Serum Life Science Europe GmbH (SLS)
Serum Life Science Europe GmbH (SLS) , founded in 2002 and formerly Vakzine Projekt Management GmbH (VPM), was established following an initiative of the German Federal Ministry of Education and Research (BMBF) to promote vaccine development within the country. With a funding support from BMBF between 2001 and 2010, our company organized and financed the preclinical and clinical development of vaccines nationwide. Our efforts involved identifying promising vaccine candidates from public German laboratories and overseeing their development until they were licensed to industrial partners. Additionally, SLS offers tailor-made hands-on services and consultancy to biopharmaceutical enterprises, private funding organizations and research groups, based on their in-depth experience and a strong network of reliable partners. SLS has acted as sponsor or sponsor-representative for more than 15 clinical trials. Since July 2018 Serum Institute of India (SIIPL) is majority shareholder of SLS.
Main roles in project
SLS will support the Cruzivax project with their expertise in translational project management. Furthermore, SLSVPM will be responsible for GxP consulting in the areas chemistry, manufacturing and control (CMC), and non-clinical and clinical development of the Traspain-based vaccine against T. cruzi. SLSVPM has extensive experience with the conduct of regulatory/scientific advice meetings with national competent authorities. Therefore, SLSVPM will perform, including the preparation, conduct and follow up, two scientific advice meetings with the national regulatory authority of Belgium. SLSVPM will also act as sponsor (according to ICH E6 (R2) and Directive 2001/20/EC) of the phase 1 clinical trial.
Contact: Dr. Leander Grode
